The Investor Presentation does confirm my suspicions above....
"Acquisition expected to add immediate additional revenue to our top line.
Increased margins will be achieved by selling fully priced products direct to customers.
Greater revenue per product sold will assist Osteopore accelerate our plan to become cash flow positive and profitable.
Significant opportunity to scale direct sales."
Ann: Activities Update Qtr Ending December 2022 and Appendix 4C, page-8
Add to My Watchlist
What is My Watchlist?
